Aflac Selloff On Intercept Article An Overreaction, Says Evercore ISI

The Intercept's article today on Aflac is "filled with hyperbole, which reduces the credibility of the claims being brought," Evercore ISI analyst Thomas Gallagher tells investors in a research note.